Marshall works extensively with both private and public companies, as well as founders, boards, and executive teams, in high-growth sectors including artificial intelligence, life sciences, software, crypto, and space and defense. His practice includes advising executives on their high-stakes employment agreements and within the context of strategic transactions.

His work spans a broad range of matters, including the design and implementation of equity incentive plans, executive compensation arrangements, and deferred compensation structures, as well as advising on compensation-related disclosures and proxy matters for public companies. He enjoys developing creative solutions to compensation-related problems and designing (or redesigning) various types of equity awards, including options, RSUs, phantom awards, profit interests, and other synthetic equity solutions.

Marshall is also deeply involved in mergers and acquisitions, financings, and other strategic transactions.

Marshall has played a significant role in a number of high-profile transactions, including:

In the life science sector:

• Day One Biopharmaceuticals in its approximately $2.5 billion acquisition by Servier and its $150M IPO
• DICE Therapeutics in its approximately $2.4 billion acquisition by Eli Lilly and its $204M IPO
• Star Therapeutics in the pending sale of its subsidiary Vega Therapeutics to Incyte for up to $2.0 billion
• Treeline Biosciences in its definitive merger agreement with Standard BioTools Inc.

In the technology sector:

• Wiz in its $32 billion acquisition by Google (the largest acquisition of a private technology company ever)
• Figma in its proposed $20 billion acquisition by Adobe (mutually abandoned by both parties)
• WhatsApp in its $19 billion acquisition by Facebook
• SentinelOne in its $1.4 billion IPO and and $50M concurrent private placement
• Gitlab in its $800 million IPO
• Compass in its $450 million IPO
• Upwork in its $212.5million IPO
• Facebook in its IPO